115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
电针通过激活 NRF2/ARE 通路减轻代谢功能障碍相关脂肪性肝病小鼠的氧化应激和铜死亡
Authors Deng J, Liao C, Liu H, Tang X, Yang Y, Yang Y, Guo X , Zhang S, Xing K, Liao M, Tang C
Received 9 October 2025
Accepted for publication 29 December 2025
Published 6 January 2026 Volume 2026:19 568066
DOI https://doi.org/10.2147/DMSO.S568066
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Rebecca Baqiyyah Conway
Junyuan Deng,1 Cai Liao,1 Hejing Liu,1 Xin Tang,1 Yan Yang,1 Yunhao Yang,2 Xiao Guo,1 Shanshan Zhang,1 Kehan Xing,1 Mei Liao,1 Chenglin Tang1
1College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing, People’s Republic of China; 2College of Acupuncture and Tuina, Chongqing University of Chinese Medicine, Chongqing, People’s Republic of China
Correspondence: Chenglin Tang, Email tangchenglin@cqmu.edu.cn
Purpose: Oxidative stress and the newly characterized mode of regulated cell death, cuproptosis, drive the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Electroacupuncture (EA) is a promising non-drug treatment, but its mechanisms are unclear. This study investigated the benefits of EA in a high-fat diet (HFD)-induced MASLD mouse model, focusing on the NRF2/ARE pathway, cuproptosis, and the gut–liver axis.
Methods: MASLD was established in C57BL/6J mice via a 16-week HFD. Mice were arbitrarily categorized into four groups: control (C, normal chow diet), model (M, HFD), EA (HFD + EA), and EA plus NRF2 inhibitor (EM, HFD + EA + inhibitor). A 4-week intervention was then conducted. Post-intervention, body weight alterations were tracked, and serum, liver tissue, and fecal specimens were gathered for subsequent examination.
Results: EA treatment significantly improved the metabolic profile, reducing body weight, lipids, and hepatic inflammation. It attenuated oxidative stress by enhancing antioxidant capacity and activated the NRF2/ARE pathway. EA also modulated cuproptosis-related genes (upregulating dihydrolipoamide S-acetyltransferase (Dlat), downregulating solute carrier family 31 member 1 (Slc31a1), ferredoxin reductase (Fdx1), and heat shock protein 70 (Hsp70)). Furthermore, EA remodeled the gut microbiota (increasing Limosilactobacillusand Ligilactobacillus) and elevated related metabolites.
Conclusion: EA ameliorates MASLD through multiple mechanisms, including regulating lipid metabolism, attenuating inflammation and oxidative stress, activating NRF2, suppressing cuproptosis, and altering the gut–liver axis, collectively contributing to hepatic improvement.
Keywords: gut microbiota, metabolomics, hepatic lipid metabolism, inflammation, mitochondrial dysfunction, antioxidant therapy
1College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing, People’s Republic of China; 2College of Acupuncture and Tuina, Chongqing University of Chinese Medicine, Chongqing, People’s Republic of China
Correspondence: Chenglin Tang, Email tangchenglin@cqmu.edu.cn
Purpose: Oxidative stress and the newly characterized mode of regulated cell death, cuproptosis, drive the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Electroacupuncture (EA) is a promising non-drug treatment, but its mechanisms are unclear. This study investigated the benefits of EA in a high-fat diet (HFD)-induced MASLD mouse model, focusing on the NRF2/ARE pathway, cuproptosis, and the gut–liver axis.
Methods: MASLD was established in C57BL/6J mice via a 16-week HFD. Mice were arbitrarily categorized into four groups: control (C, normal chow diet), model (M, HFD), EA (HFD + EA), and EA plus NRF2 inhibitor (EM, HFD + EA + inhibitor). A 4-week intervention was then conducted. Post-intervention, body weight alterations were tracked, and serum, liver tissue, and fecal specimens were gathered for subsequent examination.
Results: EA treatment significantly improved the metabolic profile, reducing body weight, lipids, and hepatic inflammation. It attenuated oxidative stress by enhancing antioxidant capacity and activated the NRF2/ARE pathway. EA also modulated cuproptosis-related genes (upregulating dihydrolipoamide S-acetyltransferase (Dlat), downregulating solute carrier family 31 member 1 (Slc31a1), ferredoxin reductase (Fdx1), and heat shock protein 70 (Hsp70)). Furthermore, EA remodeled the gut microbiota (increasing Limosilactobacillusand Ligilactobacillus) and elevated related metabolites.
Conclusion: EA ameliorates MASLD through multiple mechanisms, including regulating lipid metabolism, attenuating inflammation and oxidative stress, activating NRF2, suppressing cuproptosis, and altering the gut–liver axis, collectively contributing to hepatic improvement.
Keywords: gut microbiota, metabolomics, hepatic lipid metabolism, inflammation, mitochondrial dysfunction, antioxidant therapy